Correlation of biological aggressiveness assessed by 11C- methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 3, 2011, Pages 441-450

  Kawai, Nobuyuki ^a   Maeda, Yukito ^b   Kudomi, Nobuyuki ^a   Miyake, Keisuke ^a   Okada, Masaki ^a   Yamamoto, Yuka ^b   Nishiyama, Yoshihiro ^b   Tamiya, Takashi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

FMISO PET; Gd enhanced MRI; Glioblastoma; Hypoxia; MET PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; GADOLINIUM; METHIONINE C 11;

ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; CORRELATIONAL STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPOXEMIA; IMAGE ANALYSIS; MALE; MAXIMUM ALLOWABLE CONCENTRATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; TUMOR AGGRESSIVENESS; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; BRAIN NEOPLASMS; CELL HYPOXIA; FEMALE; GLIOBLASTOMA; HUMANS; MALE; METHIONINE; MIDDLE AGED; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; TUMOR BURDEN;

EID: 79953734435     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1645-4     Document Type: Article

References (38)

1. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127-36. (Pubitemid 47492957)
2. Swanson KR, Alvord Jr EC, Murray JD. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. Br J Cancer 2002;86:14-8. (Pubitemid 34146334)
3. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66:865-74. (Pubitemid 17085708)
4. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52. (Pubitemid 38445681)
5. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004;64: 920-7. (Pubitemid 38176893)
6. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005;15:297-310. (Pubitemid 41677429)
7. Tsang RW, Fyles AW, Milosevic M, Syed A, Pintille M, Levin W, et al. Interrelationship of proliferation and hypoxia in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000;46:95-9. (Pubitemid 30021486)
8. Slomiany MG, Rosenzweig SA. Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 2006;318:666-75. (Pubitemid 44061241)
9. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985;56:1106-11. (Pubitemid 15003495)
10. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-65. (Pubitemid 18261854)
11. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-26.
12. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-7.
13. Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HLP, Muzi M, et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 2009;50:36-44.
14. Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus R-I, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22. (Pubitemid 28240345)
15. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-70. (Pubitemid 39487701)
16. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol 2006;27:1432-7. (Pubitemid 44260122)
17. Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al. 11C-methionine (MET) and 18Ffluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 2008;35:2009-17.
18. Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishikawa K, et al. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005;103:498-507. (Pubitemid 43186642)
19. Kim S, Chung J-K, Im S-H, Jeong JM, Lee DS, Kim DG, et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:52-9. (Pubitemid 40142778)
20. Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergström M, et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 1989;30:225-32. (Pubitemid 19152548)
21. Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T, et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 2004;75:1457-62. (Pubitemid 39279817)
22. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 2006;104:238-53.
23. Ishiwata K, Ido T, Vaalburg W. Increased amounts of Denantiomer dependent on alkaline concentration in the synthesis of L-[methyl-11C]methionine. Int J Rad Appl Instrum A 1988; 39:311-4.
24. Lim JL, Berridge MS. An efficient radiosynthesis of [18F] fluoromisonidasole. Appl Radiat Isot 1993;44:1085-91.
25. Galldiks N, Ullrich R, Schroeter M, Fink GR, Jacobs AH, Kracht LW. Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging 2010;37:84-92.
26. Kinoshita M, Hashimoto N, Goto T, Yanagisawa T, Okita Y, Kagawa N, et al. Use of fractional anisotropy for determination of the cut-off value in 11C-methionine positron emission tomography for glioma. Neuroimage 2009;45:312-8.
27. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008;14:2623-30.
28. Szeto MD, Chakraborty G, Handley J, Rockne R, Muzi M, Alvord Jr EC, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 2009;69:4502-9.
29. Shimada Y, Uemura K, Ardekani BA, Nagaoka T, Ishiwata K, Toyama H, et al. Application of PET-MRI registration techniques to cat brain imaging. J Neurosci Methods 2000;101:1-7.
30. Rampling R, Cruickshank G, LewisAD, Fitzsimmons SA, Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994;29:427-31. (Pubitemid 24187904)
31. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886-92. (Pubitemid 38428715)
32. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990;122:301-8. (Pubitemid 20214420)
33. Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18Ffluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006;47:410-8. (Pubitemid 46768482)
34. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84. (Pubitemid 40053376)
35. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008;15:678-85. (Pubitemid 351405072)
36. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000;88:2606-18. (Pubitemid 30331970)
37. Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J, et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol 2002;20:3149-55. (Pubitemid 34791105)
38. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC, et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 2000;18:1254-9. (Pubitemid 30159843)